Chugai And Nippon Kayaku Drugs Benefit From Japan’s New Fast Track Review Process
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical's Xeloda (capecitabine) and Nippon Kayaku's Hycamtin (nogitecan) are to benefit from a new fast review process installed by Japan's Ministry of Health, Labor and Welfare to accelerate the approval process for drugs with high medical need